摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-甲基嘧啶)苯胺 | 175201-90-8

中文名称
3-(2-甲基嘧啶)苯胺
中文别名
4-(3-氨基苯基)-2-甲基嘧啶
英文名称
3-(2-methylpyrimidin-4-yl)phenylamine
英文别名
4-(3-aminophenyl)-2-methylpyrimidine;3-(2-Methylpyrimidin-4-yl)aniline
3-(2-甲基嘧啶)苯胺化学式
CAS
175201-90-8
化学式
C11H11N3
mdl
MFCD00067950
分子量
185.228
InChiKey
DMWKPJRZFGLSAX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    108 °C
  • 沸点:
    375.2±25.0 °C(Predicted)
  • 密度:
    1.159±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    51.8
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26
  • 危险类别码:
    R36/37/38

SDS

SDS:c0049eb452d00aa690167cb2026af181
查看
Name: 3-(2-Methylpyrimidin-4-yl)aniline 97% Material Safety Data Sheet
Synonym:
CAS: 175201-90-8
Section 1 - Chemical Product MSDS Name:3-(2-Methylpyrimidin-4-yl)aniline 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
175201-90-8 3-(2-Methylpyrimidin-4-yl)aniline 97% unlisted
Hazard Symbols: XN
Risk Phrases: 20/21/22

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175201-90-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 107 - 110 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H11N3
Molecular Weight: 185

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, ammonia.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175201-90-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(2-Methylpyrimidin-4-yl)aniline - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 175201-90-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175201-90-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175201-90-8 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    3-(2-甲基嘧啶)苯胺2-氯-5-硝基苯甲酰氯2,4-滴二甲胺盐 作用下, 以52%的产率得到N-[3-(2-Methylpyrimidin-4-yl)phenyl]-(2-chloro-5-nitrophenyl)carboxamide
    参考文献:
    名称:
    PPAR-gamma modulator
    摘要:
    以下化学式的化合物或其药理学上可接受的盐:其中A代表苯基或类似物,B代表芳基或类似物,X代表氧原子或类似物,n代表0或1。该化合物是一种PPAR &ggr; 调节剂,用于治疗逆行性骨质疏松症,通过抑制脂肪细胞的过度分化并促进干细胞向成骨细胞的形成和分化,以及用于糖尿病而不具有过度脂肪生成、肝功能障碍、血管紊乱、心脏疾病等特征。
    公开号:
    US20030134859A1
点击查看最新优质反应信息

文献信息

  • [EN] 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS<br/>[FR] 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES ET 4-PYRAZOLYL-N-HÉTÉROARYLPYRIMIDIN-2-AMINES EN TANT QU'INHIBITEURS DE JANUS KINASE
    申请人:INCYTE CORP
    公开号:WO2009064835A1
    公开(公告)日:2009-05-22
    The present invention provides substituted bicyclic heteroaryl compounds, 5 including, for example, 4-pyrazoIyI-N-arylpyrirnidin-2-arnines and 4-pyrazolyl-N-heteroarylpyτimidin-2-amines that modulate the activity of kinases and are useful in the treatment of diseases related to activity of kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.formule :(1)
    本发明提供了取代的双环杂环芳基化合物,包括例如4-吡唑基-N-芳基吡啶-2-胺和4-吡唑基-N-杂环芳基嘧啶-2-胺,这些化合物调节激酶的活性,在治疗与激酶活性相关的疾病方面具有用处,例如免疫相关疾病、皮肤疾病、髓细胞增生性疾病、癌症和其他疾病。公式:(1)
  • COMPOUNDS AND METHODS FOR TREATING CANCER
    申请人:ANTIDOTE IP HOLDINGS, LLC
    公开号:US20200299282A1
    公开(公告)日:2020-09-24
    Substituted cinnamamide compounds and analogs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or ameliorate cancer are provided.
    提供了替代肉桂酰胺化合物和类似物、制备这类化合物的方法、包含这类化合物的药物组合物和药物、以及使用这类化合物治疗、预防或改善癌症的方法。
  • Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
    申请人:Cytovia, Inc.
    公开号:US20030069239A1
    公开(公告)日:2003-04-10
    The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I: 1 wherein A, Ar 1 , Ar 2 , R 1 and R 3 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    本发明涉及被一般式I所代表的取代的2-芳基-4-芳基氨基嘧啶及其类似物: 其中A,Ar1,Ar2,R1和R3在此处被定义。本发明还涉及发现具有式I的化合物是caspase的激活剂和凋亡诱导剂。本发明的化合物可用于诱导在出现未受控制的异常细胞生长和扩散的各种临床病况中的细胞死亡。
  • [EN] 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS DE L'ACIDE CARBOXYLIQUE PHÉNOXYCHROMANE SUBSTITUÉS EN 6
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2009158426A1
    公开(公告)日:2009-12-30
    Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
    式(I)的化合物:其中A1、A2、W、L、G、R7a、R7b、R8、R9和R10具有规范中给定的含义,是DP2受体调节剂,可用于治疗免疫性疾病。
  • SUBSTITUTED 2-PYRIDONE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENT
    申请人:PEUKERT Stefan
    公开号:US20070281948A1
    公开(公告)日:2007-12-06
    This invention relates to compounds of formula (I), wherein R1 and R3 independently represent fluorine, methoxy, —OCF 3 , C 2 -C 3 -alkenyl or C 1 -C 4 -alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; R2 represents hydrogen, fluorine, methoxy, —OCF 3 , C 2 -C 3 -alkenyl or C 1 -C 4 -alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; X represents O, S, NH or N(C 1 -C 3 -alkyl); and Ar represents an unsubstituted or at least monosubstituted aryl or heteroaryl. Said compounds are inhibitors of poly(ADP-ribose) polymerase (PARP), and may be used for the treatment of a variety of disorders.
    该发明涉及式(I)的化合物,其中R1和R3分别代表氟、甲氧基、—OCF3、C2-C3-烯基或C1-C4-烷基,该烷基可选择地由氯、甲氧基或一个、两个或三个氟原子取代;R2代表氢、氟、甲氧基、—OCF3、C2-C3-烯基或C1-C4-烷基,该烷基可选择地由氯、甲氧基或一个、两个或三个氟原子取代;X代表O、S、NH或N(C1-C3-烷基);Ar代表未取代或至少单取代的芳基或杂芳基。这些化合物是聚(ADP-核糖)聚合酶(PARP)的抑制剂,可用于治疗各种疾病。
查看更多